The investigational drug BMS-986365 may help patients with mCRPC previously treated with ARPIs overcome drug resistance, despite their genomic status. The investigational dual androgen receptor ...

Please provide your email address to receive an email when new articles are posted on . Additionally, researchers found enzalutamide (Xtandi; Astellas, Pfizer), an androgen receptor antagonist, to be ...

An international group of scientists studying the tendency of intrinsically disordered proteins to form biomolecular condensates report that they have found that the mechanisms involved in ...

Prostate cancer hijacks the normal prostate's growth regulation program to release the brakes and grow freely, according to Weill Cornell Medicine researchers. The discovery, published Dec. 13 in ...

The dinuclear platinum(II) complexes inhibit prostate cancer cell growth by binding to the androgen receptor (AR) and disrupting AR-mediated gene expression. This mechanism leads to apoptosis and ...

Most patients with nonmetastatic castration-resistant prostate cancer were able to stay on their therapies long-term, research showed. The recent DEAR trial showed that most patients with ...

Is all prostate cancer testosterone receptor-positive? —Mike Hutchins, MD, Missoula, Mont. Yes, all prostate cells have androgen receptors. This is the reason prostate cancer will respond to androgen ...

Please provide your email address to receive an email when new articles are posted on . Androgen receptor activation counteracted high levels of ER activity. The findings suggest that androgen ...